SEP 228432
Alternative Names: SEP-225432Latest Information Update: 05 Nov 2023
At a glance
- Originator Sepracor
- Developer Sumitomo Pharma America
- Class Antidepressants
- Mechanism of Action Adrenergic uptake inhibitors; Dopamine uptake inhibitors; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Major depressive disorder; Neuropathic pain
- Discontinued Attention-deficit hyperactivity disorder
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for phase-I development in Major depressive disorder in USA (PO)
- 04 Nov 2017 No recent reports of development identified for phase-I development in Neuropathic-pain in USA (PO)
- 29 Aug 2012 Sunovion Pharmaceuticals completes a phase I trial in healthy volunteers in USA (NCT01531972)